Cyclacel Pharmaceuticals (NASDAQ:CYCC) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) released its earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01), Morningstar.com reports.

CYCC stock opened at $0.46 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.09 and a quick ratio of 8.09. The company has a fifty day moving average price of $0.56 and a two-hundred day moving average price of $0.70. Cyclacel Pharmaceuticals has a one year low of $0.28 and a one year high of $1.87. The stock has a market cap of $7.65 million, a price-to-earnings ratio of -0.74 and a beta of 2.98.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the quarter. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 at the end of the most recent reporting period. 5.36% of the stock is owned by institutional investors and hedge funds.



Several equities analysts recently weighed in on CYCC shares. Zacks Investment Research cut shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. HC Wainwright reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a research note on Wednesday, May 15th. Finally, Roth Capital reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a research note on Thursday, May 23rd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cyclacel Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $5.00.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

See Also: Why is total return important?

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.